Major milestone reached for Myeloma UK Clinical Trial Network with publication of data from MUK one

Data from MUK one, the first trial to be conducted through the Myeloma UK Clinical Trial Network (CTN) have been published in the British Journal of Haematology. MUK one, a Phase II multicentre, open label, randomised trial aimed to identify the optimal starting dose of bendamustine when given in combination with thalidomide and dexamethasone in relapsed…

April 21, 2015

Details

MUK one data reveals optimal dose for bendamustine in the treatment of relapsed and/or refractory myeloma

Data from MUK one, the first trial to be conducted through the Myeloma UK Clinical Trial Network (CTN) has been published in the British Journal of Haematology. The publication represents a major milestone for the CTN by marking the completion of its first trial. MUK one, a Phase II multicentre, open label, randomised trial aimed…

April 21, 2015

Details